KR20030088742A - Whitening external application(Cosmetics) contains cysteine and it's derivatives or erdosteine - Google Patents

Whitening external application(Cosmetics) contains cysteine and it's derivatives or erdosteine Download PDF

Info

Publication number
KR20030088742A
KR20030088742A KR1020020026597A KR20020026597A KR20030088742A KR 20030088742 A KR20030088742 A KR 20030088742A KR 1020020026597 A KR1020020026597 A KR 1020020026597A KR 20020026597 A KR20020026597 A KR 20020026597A KR 20030088742 A KR20030088742 A KR 20030088742A
Authority
KR
South Korea
Prior art keywords
skin
derivatives
whitening
erdosteine
cosmetics
Prior art date
Application number
KR1020020026597A
Other languages
Korean (ko)
Inventor
심창구
우건희
Original Assignee
주식회사 비봉파인
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 주식회사 비봉파인 filed Critical 주식회사 비봉파인
Priority to KR1020020026597A priority Critical patent/KR20030088742A/en
Publication of KR20030088742A publication Critical patent/KR20030088742A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A61K8/44Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
    • A61K8/447Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof containing sulfur
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/4986Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with sulfur as the only hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00Preparations for care of the skin
    • A61Q19/02Preparations for care of the skin for chemically bleaching or whitening the skin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Birds (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Cosmetics (AREA)

Abstract

PURPOSE: Provided is a skin whitening composition containing, as active ingredients, cysteine and its derivatives or erdosteine. It improves freckles, has skin whitening and melanin inhibition effects and is free from toxicity. CONSTITUTION: A skin whitening composition is characterized by containing 0.01-20.0 wt.% of cysteine and its derivatives or erdosteine as active ingredients and formulated into cream, lotion, a mask pack and the like.

Description

시스테인 및 그 유도체 또는 에르도스테인을 함유하는 미백용 조성물{Whitening external application(Cosmetics) contains cysteine and it's derivatives or erdosteine}Whitening external application (Cosmetics) contains cysteine and it's derivatives or erdosteine}

본 발명은 피부 미백 효과가 우수한 조성물에 관한 것으로 좀 더 자세하게는 시스테인 및 그 유도체 또는 에르도스테인을 유효성분으로 하여 피부 색소 과침착을 방어해주고 피부에 침착된 멜라닌 색소의 색을 엷게 하여 도움을 주는 미백용 피부 외용제 조성물에 관한 것이다.The present invention relates to a composition having excellent skin whitening effect, and more particularly, to protect skin pigment overdeposition by using cysteine and its derivatives or erdostain as an active ingredient and to help by thinning the color of melanin pigment deposited on the skin. A skin external preparation composition for whitening.

사람의 피부색은 인종별, 성별, 연령별, 지역, 계절, 부위별로 다르며 건강상태나 순간적인 흥분상태에 따라서도 변화한다.Human skin color varies by race, sex, age, region, season and region, and also changes according to health or momentary excitement.

피부색을 결정하는 인자를 살펴보면 멜라닌, 멜라노이드, 카로틴, 헤모글로빈등의 색소가 상호 작용하여 피부색을 나타내는데 그 중에서도 피부색에 가장 중요한 역할을 하는 것은 멜라닌 색소이다.Looking at the factors that determine the skin color, melanin, melanoids, carotene, hemoglobin and other pigments interact with each other to represent the skin color, the most important role of the skin color is melanin pigment.

이 멜라닌은 표피의 기저층에 분포되어 있는 멜라노사이트내의 소기관인 멜라노좀에서 합성된다.This melanin is synthesized in melanosomes, which are organelles in melanocytes distributed in the basal layer of the epidermis.

멜라닌의 합성 경로는 아미노산의 일종인 타이로신을 출발 물질로 하여 표피의 기저층에 존재하는 멜라닌세포의 내부에 함유되어 있는 타이로시나제(tyrosinase)라는 효소에 의해 도파(DOPA, dihydroxyphenylalanine), 도파퀴논이 되고 계속 산화하여 멜라닌이 합성되는 산화과정이다.Synthetic pathways of melanin are derived from tyrosinase (DOPA, dihydroxyphenylalanine) and dopaquinone by enzymes tyrosinase contained in the melanocytes in the basal layer of the epidermis. It is an oxidation process in which melanin is synthesized by continuously oxidizing.

이러한 산화과정으로 만들어진 멜라닌은 각질형성세포인 케라티노사이트로 들어가 점차로 피부 바깥쪽으로 이동하게되며 각질층이 되어 체외로 떨어져나간다. 정상적인 피부라면 이러한 과정이 반복적으로 일어나 피부색을 유지한다. 하지만 비정상적으로 각화과정이 길어지거나 타이로신의 산화를 촉진하는 외부 원인에 영향을 받을 경우 색소 침착이 일어날 수 있으며 피부색에 변화가 생기게 된다.The melanin produced by this oxidation process enters keratinocytes, keratinocytes, and gradually moves out of the skin and falls off to the stratum corneum. If you have normal skin, this process will happen repeatedly to maintain your skin color. However, abnormally prolonged keratinization or external factors that promote the oxidation of tyrosine can lead to pigmentation and skin color changes.

따라서. 피부색소 이상증의 치료와 미용적 욕구충족을 위한 미백제에 대한 개발이 활발히 이루어지고 있다.therefore. The development of whitening agents for the treatment of skin pigmentation disorder and satisfying cosmetic needs is being actively made.

그 구체적인 예를 들면, 코직산(kojic acid), 알부틴(arbutin)등과 같은 타이로시나제 활성을 저해하는 억제제들, 하이드로퀴논(hydroquinone), 비타민 A, 비타민 C 및 이들의 유도체 등이 있다. 그러나, 이들은 피부에 대한 안전성, 제형 내에서의 안정성 및 미백효과의 불충분으로 인해 그 사용이 제한 되고 있다.Specific examples thereof include inhibitors that inhibit tyrosinase activity such as kojic acid, arbutin and the like, hydroquinone, vitamin A, vitamin C and derivatives thereof. However, they are limited in their use due to insufficient skin safety, stability in formulations and whitening effects.

또한 이들 미백제 이외의 물질로 천연물중 미백 활성성분을 찾기 위한 노력이 계속되고있는데 상백피, 감초등 다수의 식물추출물이 타이로시나제에 작용하여 멜라닌 생성을 억제한다는 사실이 밝혀졌으나 이들 역시 안전성, 안정성 변색가능성의 문제로 유효농도 이상 사용하는데 문제점을 가지고 있다.In addition, efforts have been made to find whitening active ingredients in natural products with substances other than these whitening agents, and it has been found that many plant extracts such as lettuce, licorice and licorice inhibit melanin production by acting on tyrosinase. There is a problem in using more than the effective concentration due to the problem of discoloration.

[시스테인의 타이로시나제활성 억제 메카니즘][Cysteine's Tyrosinase Activity Inhibition Mechanism]

[ Erdosteine의 타이로시나제 활성 억제 메카니즘 ][Mechanism of Inhibition of Tyrosinase Activity by Erdosteine]

본 발명자는 상기와 같은 문제점을 해결하기 위한 물질을 찾고자 연구한 결과, 낮은 농도에서 미백효과가 우수하면서, 피부 부작용이 적은 안전한 피부 외용제 조성물을 제공하는 것이다.The present inventors have studied to find a substance for solving the above problems, to provide a safe skin external preparation composition excellent in whitening effect at a low concentration, less skin side effects.

상기한 본 발명의 목적은 독성이나 안전성면에서 문제가 없으며 미백효과를 나타내는 조성물을 제공하는 것으로 특징 및 장점은 하기 발명의 상세한 설명으로부터 명백하게 될 것이다.The object of the present invention described above is to provide a composition that exhibits a whitening effect without any problem in terms of toxicity or safety, and its features and advantages will become apparent from the following detailed description.

본 발명의 미백용 피부 외용제 조성물은 시스테인 및 그 유도체 0.1 ∼ 20.0 중량% 함유함을 특징으로 하며, 각 성분의 함량은 세포배양 수준에서 효과를 나타내는 최소농도와 제형화 측면에서 배합할 수 있는 최대농도의 범위에서 결정되었다.The skin whitening composition for skin whitening of the present invention is characterized by containing 0.1 to 20.0% by weight of cysteine and its derivatives, and the content of each component is the minimum concentration that shows the effect at the level of cell culture and the maximum concentration that can be formulated in terms of formulation. Was determined in the range of.

본 발명의 피부 외용제 조성물은 기미, 주근깨, 노인성 색소반 등의 피부색소 이상증을 치료 또는 예방하기 위한 목적으로 사용되는 것으로, 그 제형에 있어서 특별히 한정되는 바가 없으며, 예를 들면, 유연화장수, 영양화장수, 마사지크림, 영양크림, 팩, 젤 또는 피부 점착 타입의 화장료의 제형을 갖는 화장료 조성물일 수 있으며, 또한 크림, 로션, 겔, 패취 또는 분무제와 같은 경피투여형 제형일 수 있다.The external preparation composition for skin of the present invention is used for the purpose of treating or preventing skin pigmentation disorders such as blemishes, freckles, and senile plaques, and is not particularly limited in the formulation thereof. For example, supple cosmetics and nutrient cosmetics It may be a cosmetic composition having a formulation of a massage cream, a nourishing cream, a pack, a gel, or a skin adhesive type cosmetic, and may also be a transdermal dosage form such as a cream, lotion, gel, patch or spray.

그리고, 각 제형의 미백용 피부 외용제 조성물에 있어서, 상기한 성분들 이외에 자외선차단제등 다른 성분들을 기타 피부 외용제 조성물의 제형 또는 사용 목적 등에 따라 자유로이 배합할 수 있다.In addition, in the skin external preparation composition for whitening of each formulation, other ingredients such as sunscreen may be freely blended according to the formulation or purpose of use of the other skin external preparation composition.

이하 각종 예를 들어 본 발명을 보다 상세히 설명하지만 본 발명이 이들 예에만 국한되는 것은 아니다.Hereinafter, the present invention will be described in more detail with reference to various examples, but the present invention is not limited to these examples.

실시처방예Implementation example

1) 크림 처방 예1) Cream prescription example

2) 로션 처방2) lotion prescription

3) 화장수 처방3) lotion prescription

4) 팩 처방4) pack prescription

(시험예 1) Mushroom Tyrosinase AssayTest Example 1 Mushroom Tyrosinase Assay

Tyrosinase 활성을 억제하는 Tyrosinase Inhibitor를 농도별로 비교, 평가하는데 그 목적이 있다.The purpose of this study is to compare and evaluate Tyrosinase Inhibitors that inhibit tyrosinase activity.

각 제형의 시험제품과 비교제품을 비교하여 타이로시나제의 활성 억제능을 측정하였다.The inhibitory activity of tyrosinase was determined by comparing the test product and the comparative product of each formulation.

① 타이로시나제 활성 측정법① Tyrosinase activity assay

검체(제조예) 및 대조군(비교예)을 하기와 같은 방법으로 37℃ 항온조에서 30분간 반응하여 각각에 대해 475 nm부근의 최대흡수값(Optical Density)을 측정하고 아래 계산식1에 따라 계산하였다.Specimens (preparation example) and control (comparative example) was reacted for 30 minutes in a 37 ℃ thermostat in the following manner to measure the maximum optical density of the vicinity of 475 nm (Optical Density) for each was calculated according to the formula 1 below.

기타 일반적인 사항은 공지된 방법으로 측정하였다.Other general matters were measured by known methods.

(계산식1)(Calculation 1)

타이로시나제 활성억제율(%) = 검체흡광도(OD) / 대조군흡광도(OD) × 100Tyrosinase activity inhibition rate (%) = sample absorbance (OD) / control absorbance (OD) × 100

(결 과)(result)

(시험예 2) 동물수준에서의 미백 효과 평가(Test Example 2) Evaluation of the whitening effect at the animal level

갈색 몰모트(Tortoiseshell guinea pigs; Brown guinea pigs)는 사람과 같이 자외선, 알레르기 반응 등에 의해 색소침착이 생기는 동물이며, 털과 피부의 빛깔이 동일하기 때문에 털의 빛깔이 균일하고 갈색인 것을 고르면, 털을 제거한 뒤에 광범위한 부위를 사용할 수 있다. 하기에 열거한 방법으로 색소침착을 생기게 하고, 그 색소침착 부위에 미백 조성물을 도포하는 방법에 의해, 색소침착의 개선효과를 검증할 수 있다. 또한, 이 방법으로 효과가 인정된 물질은, 사람의 자외선 색소반에서의 평가에도 효과가 나타날 확률이 높기 때문에 일차 생체 내 검색법으로 유용하게 사용된다.Brown guinea pigs (Tortoiseshell guinea pigs) are animals that cause pigmentation due to ultraviolet rays, allergic reactions, etc., like humans, and because hair and skin have the same color, the hair color is uniform and brown. After removal, a wide range of sites can be used. Pigmentation is produced by the method enumerated below, and the improvement effect of pigmentation can be verified by the method of apply | coating the whitening composition to the pigmentation site | part. In addition, substances whose effects have been recognized by this method are useful in primary in vivo screening methods because they have a high probability of having an effect on evaluation in human ultraviolet pigmented plaques.

① 자외선 색소반의 제작법① Preparation of UV Pigment

자외선(UVB)에 의한 색소침착의 제작은, 갈색 몰모트 배후의 털을 제거한 피부에 2×2cm의 정방형의 창문이 8개 뚫린 차광용 알루미늄 호일을 접착시킨 후, SE 램프(파장 290∼320nm, Toshiba)로 자외선(UVB)을 조사하였다(총조사 에너지량은 1350mJ/cm2). 조사 후 알루미늄 호일을 벗겨내고 아래와 같은 방법의 도포방법으로 시험물질의 미백효과를 평가하였다. 자외선 조사 후 색소침착은 2-3일 뒤에 나타나며, 약 2주 후에 최고에 달한다. 생성된 자외선 색소반의 색조가 동일하며 얼룩이 생기지 않는 것이 중요하고, 자외선 색소반의 형성이 좋지 않은 개체는 좋은 결과를 위해 쓰지 않는 편이 좋다.Preparation of pigmentation by ultraviolet (UVB) is performed by attaching SE light (wavelength 290 to 320nm, Toshiba) after bonding 8 x 2x2cm square window-shielded aluminum foil to the skin from which the hairs behind the brown molot are removed. ) Was irradiated with ultraviolet light (UVB) (total amount of irradiation energy 1350mJ / cm 2). After irradiation, the aluminum foil was peeled off and the whitening effect of the test substance was evaluated by the application method as follows. Pigmentation after UV irradiation appears 2-3 days later, reaching peak after about 2 weeks. It is important that the resulting UV pigments have the same color tone and that no stains occur. Individuals with poor UV pigment formations should not be used for good results.

② 조성물의 도포방법② Application of Composition

자외선 조사 후 시험물질을 함유한 제품(실시예, 비교예)을 14일 뒤에 도포하기 시작하였다. 도포회수는 1일 2회로 50일간 계속하였다. 검체는 면봉으로 도포하고, 다른 부위에 반드시 용매를 도포하는 대조부위를 마련하였다. 효과 판정과 함께 누적자극성 여부도 관찰하였다After UV irradiation, the product containing the test substance (Example, Comparative Example) was started after 14 days. The application number of times was continued for 50 days twice a day. Specimens were applied with a cotton swab and a control site was prepared to apply the solvent to other sites. Along with the determination of the effect, the cumulative stimulus was also observed.

③ 효과의 판정③ judgment of effect

색차계를 사용하여 피부의 흑백정도를 측정하여 효과를 판정하였다. 색을 표시하는 데에는 L*a*b* 표색계를 사용하며, 본 발명에서는 주로 L* 값(명도)을 지표로 하였다. L* 값은 표준 백판으로 교정하며, 측정은 1개 부위에 5회 이상 측정을 되플이함으로써 색소침착부를 균등하게 측정한다.The effect was determined by measuring the degree of black and white of the skin using a color difference meter. L * a * b * colorimeter is used for displaying a color, and in this invention, L * value (brightness) was mainly used as an index. The L * value is calibrated with a standard whiteboard and the measurements are measured evenly by repeating the measurements five times or more at one site.

도포 시작시점과 완료시점에서의 피부색의 차이(△L*)를 하기 계산식 2에 따라 계산하고, 이를 결과 에 나타내었다. 미백효과는 시료 도포 부위와 대조군 부위의 △L*의 비교로 판정하는데, △L*값이 2정도일 경우는 침착된 색소의 미백화가 뚜렷한 경우이고, 1.5정도 이상이면 미백효과가 있다고 판정할 수 있다.The difference in skin color (ΔL *) at the start of application and at the end of the application was calculated according to the following Equation 2, which is shown in the results. The whitening effect is determined by comparing ΔL * between the sample application site and the control site. When ΔL * value is about 2, the whitening effect of the deposited pigment is clear, and when about 1.5 or more, the whitening effect may be determined. .

(계산식 2)(Calculation 2)

피부색의 차이(△L*) = 도포시험완료 후의 L*값 - 도포시작 전 L*값Difference in skin color (△ L *) = L * value after completion of application test-L * value before application start

(결 과)(result)

상기한 바와 같이 본 발명에 따른 시스테인 및 그 유도체 또는 에르도스테인을 함유한 미백용 조성물은 사람에게 사용했을 때 매우 안전하면서도 색소 침착을 감소시키는 효과가 우수하다. 한편, 멜라닌 합성에 역할을 하는 효소인 타이로시나제의 합성 또는 활성을 억제시키는 작용 및 효과를 지니며 미백에 효과가 있는 추출물이나 미백물질을 혼합하여 제조된 혼합추출물을 사용하면 미백 효과면에서 상승효과가 나타나며 자외선차단제를 추가 혼합하면 1차 멜라닌 형성 원인을 미연에 방지하여 효능이 배가된다.As described above, the composition for whitening containing cysteine and its derivatives or erdostain according to the present invention is very safe when used in humans and has an excellent effect of reducing pigmentation. On the other hand, using a mixed extract prepared by mixing an extract or a whitening substance that has the effect and effect of inhibiting the synthesis or activity of tyrosinase, an enzyme that plays a role in melanin synthesis, in terms of whitening effect A synergistic effect is seen and additional mixing with sunscreen prevents the cause of primary melanin formation and doubles its efficacy.

Claims (2)

시스테인 및 그 유도체 또는 에르도스테인을 유효성분으로 포함하되 0.01 ∼ 20.0 중량% 함유하는 것을 특징으로 하는 미백용 조성물A whitening composition comprising cysteine and derivatives thereof or erdostein as an active ingredient and containing 0.01 to 20.0 wt% 상기 제 1 항의 제형이 크림, 로션, 화장수, 팩으로 이루어 진 미백용 조성물.The composition of claim 1, wherein the formulation of the cream, lotion, lotion, pack.
KR1020020026597A 2002-05-14 2002-05-14 Whitening external application(Cosmetics) contains cysteine and it's derivatives or erdosteine KR20030088742A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020020026597A KR20030088742A (en) 2002-05-14 2002-05-14 Whitening external application(Cosmetics) contains cysteine and it's derivatives or erdosteine

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1020020026597A KR20030088742A (en) 2002-05-14 2002-05-14 Whitening external application(Cosmetics) contains cysteine and it's derivatives or erdosteine

Publications (1)

Publication Number Publication Date
KR20030088742A true KR20030088742A (en) 2003-11-20

Family

ID=32382803

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020020026597A KR20030088742A (en) 2002-05-14 2002-05-14 Whitening external application(Cosmetics) contains cysteine and it's derivatives or erdosteine

Country Status (1)

Country Link
KR (1) KR20030088742A (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1502576A3 (en) * 2003-07-31 2005-06-22 L'oreal Composition containing a 2-thioacetamide and use thereof for stimulating growth or preventing fall out of keratin fibres
CN104352399A (en) * 2014-10-20 2015-02-18 周羿 Preparation method for freckle removing cream
WO2022250348A1 (en) * 2021-05-26 2022-12-01 경북대학교 산학협력단 Skin whitening use of cysteine derivative

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06336418A (en) * 1993-05-28 1994-12-06 Kose Corp Cosmetic
JPH07258024A (en) * 1994-03-28 1995-10-09 Kaiyo Bio Technol Kenkyusho:Kk Melanin formation inhibitor
JPH10182404A (en) * 1996-12-24 1998-07-07 Kose Corp Preparation for external use for skin
JP2002060318A (en) * 2000-10-03 2002-02-26 Noevir Co Ltd Skin care preparation

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06336418A (en) * 1993-05-28 1994-12-06 Kose Corp Cosmetic
JPH07258024A (en) * 1994-03-28 1995-10-09 Kaiyo Bio Technol Kenkyusho:Kk Melanin formation inhibitor
JPH10182404A (en) * 1996-12-24 1998-07-07 Kose Corp Preparation for external use for skin
JP2002060318A (en) * 2000-10-03 2002-02-26 Noevir Co Ltd Skin care preparation

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1502576A3 (en) * 2003-07-31 2005-06-22 L'oreal Composition containing a 2-thioacetamide and use thereof for stimulating growth or preventing fall out of keratin fibres
CN104352399A (en) * 2014-10-20 2015-02-18 周羿 Preparation method for freckle removing cream
WO2022250348A1 (en) * 2021-05-26 2022-12-01 경북대학교 산학협력단 Skin whitening use of cysteine derivative

Similar Documents

Publication Publication Date Title
KR101823036B1 (en) Inhibitor of melanin synthesis and the cosmetic composition containing the same
US7014844B2 (en) Lightening compositions and methods of use
EP2316411B1 (en) Compositions comprising a skin-lightening resorcinol and a skin darkening agent
KR20060130631A (en) Holistic composition and method for reducing skin pigmentation
US20100104524A1 (en) Cosmetic composition for skin whitening comprising arctiin, arctigenin or the mixture thereof as active
KR101072133B1 (en) Skin whitening composition having synergic whitening effect
US9079047B2 (en) Cosmetic composition for skin whitening
CN114681358B (en) Tyrosinase activity inhibitor and skin care product with synergistic whitening effect
CN111388382A (en) Composition for whitening and brightening skin and application of composition in cosmetics
KR100348822B1 (en) Cosmetic compositions for skin whitening containing extract of galenical medicines
KR20010060882A (en) A composition for external application for skin whitening
KR20070089327A (en) Composition for external application for skin whitening
Shaikh et al. A Review on Anti-ageing and Whitening effect
KR101309569B1 (en) Depigmenting or brightening cosmetic composition comprising at least one oxazoline as an active ingredient
KR100795514B1 (en) Composition for skin whitening containing diosgenin
KR20030088742A (en) Whitening external application(Cosmetics) contains cysteine and it's derivatives or erdosteine
CN115400067A (en) Skin whitening composition
KR100738434B1 (en) Cosmetic composition containing pyrrolidinyl diaminopyrimidine oxide
KR100406124B1 (en) Skin whitening cosmetic formulations co-containing melanogenesis inhibitors and UV B irradiation- induced prostaglandin synthesis inhibitors in skin cells
KR20150017207A (en) Compositions comprising Atractyloides japonica rhizome extract and Tranexamic acid for whitening
KR100472104B1 (en) A composition for external application for skin whitening
KR100965085B1 (en) Composition for cosmetic application having skin whitening function
KR101044597B1 (en) Cosmetic compostions comprising andiroba oils
KR100415278B1 (en) Skin whitening compositions using the Fragrance
JP2731329B2 (en) Skin cosmetics

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E601 Decision to refuse application